Two Blokes

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

  • click to rate
    Posted by Two Blokes Jul 10 - Filed in Stock - 4 views
    Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going after patients ages 2 to < 7 years.